Wetzel Investment Advisors, Inc. Esperion Therapeutics, Inc. Transaction History
Wetzel Investment Advisors, Inc.
- $176 Million
- Q1 2024
A detailed history of Wetzel Investment Advisors, Inc. transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Wetzel Investment Advisors, Inc. holds 5,000 shares of ESPR stock, worth $12,150. This represents 0.01% of its overall portfolio holdings.
Number of Shares
5,000
Previous 1,000
400.0%
Holding current value
$12,150
Previous $3,000
333.33%
% of portfolio
0.01%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ESPR
# of Institutions
180Shares Held
126MCall Options Held
2.07MPut Options Held
1.01M-
Orbimed Advisors LLC San Diego, CA13.7MShares$33.3 Million0.83% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.94MShares$24.2 Million0.42% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT9.13MShares$22.2 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.83MShares$21.4 Million0.0% of portfolio
-
Great Point Partners LLC Greenwich, CT8MShares$19.4 Million5.25% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $162M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...